S Rosenthal1, R Chen, S Hadler. 1. National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
OBJECTIVE: To determine the impact of the introduction of acellular pertussis vaccine for the fourth and fifth doses of the diphtheria and tetanus toxoids and pertussis vaccine series in children on rates of reported vaccine-associated adverse events in the United States. DESIGN: Analysis of postmarketing vaccine adverse event data from the Vaccine Adverse Event Reporting System during the years 1991 to 1993. POPULATION STUDIED: Approximately 27 million doses of diphtheria and tetanus toxoids and pertussis vaccine and 5 million doses of diphtheria and tetanus toxoids and acellular pertussis vaccine were distributed from 1991 to 1993 to children 15 months to 7 years of age. MAIN OUTCOME MEASURES: Rates of reported fever, seizures, and hospitalizations after pertussis vaccination. RESULTS: Rates of reported adverse events per 100,000 vaccinations were significantly lower after administration of diphtheria and tetanus toxoids and acellular pertussis vaccine than diphtheria and tetanus toxoids and pertussis vaccine for the following outcomes: all reports, 2.9 vs 9.8; fever, 1.9 vs 7.5; seizures, 0.5 vs 1.7; and hospitalizations, 0.2 vs 0.9. CONCLUSIONS: These results confirm that minor adverse events are less frequent after administration of the acellular pertussis vaccine. In addition, these data suggested that seizures and hospitalizations associated with pertussis vaccination are less frequent after administration of the acellular pertussis vaccine in age groups for which it is now recommended.
OBJECTIVE: To determine the impact of the introduction of acellular pertussis vaccine for the fourth and fifth doses of the diphtheria and tetanus toxoids and pertussis vaccine series in children on rates of reported vaccine-associated adverse events in the United States. DESIGN: Analysis of postmarketing vaccine adverse event data from the Vaccine Adverse Event Reporting System during the years 1991 to 1993. POPULATION STUDIED: Approximately 27 million doses of diphtheria and tetanus toxoids and pertussis vaccine and 5 million doses of diphtheria and tetanus toxoids and acellular pertussis vaccine were distributed from 1991 to 1993 to children 15 months to 7 years of age. MAIN OUTCOME MEASURES: Rates of reported fever, seizures, and hospitalizations after pertussis vaccination. RESULTS: Rates of reported adverse events per 100,000 vaccinations were significantly lower after administration of diphtheria and tetanus toxoids and acellular pertussis vaccine than diphtheria and tetanus toxoids and pertussis vaccine for the following outcomes: all reports, 2.9 vs 9.8; fever, 1.9 vs 7.5; seizures, 0.5 vs 1.7; and hospitalizations, 0.2 vs 0.9. CONCLUSIONS: These results confirm that minor adverse events are less frequent after administration of the acellular pertussis vaccine. In addition, these data suggested that seizures and hospitalizations associated with pertussis vaccination are less frequent after administration of the acellular pertussis vaccine in age groups for which it is now recommended.
Authors: Daniel B Hawcutt; Nicki-Jayne Russell; Hannah Maqsood; Koushan Kouranloo; Simon Gomberg; Catriona Waitt; Andrew Sharp; Andrew Riordan; Mark A Turner Journal: Br J Clin Pharmacol Date: 2016-09-12 Impact factor: 4.335
Authors: Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark Journal: MMWR Recomm Rep Date: 2018-04-27
Authors: Ronald Gold; Luis Barreto; Santiago Ferro; John Thippawong; Roland Guasparini; William Meekison; Margaret Russell; Elaine Mills; Dana Harrison; Pierre Lavigne Journal: Can J Infect Dis Med Microbiol Date: 2007-07 Impact factor: 2.471